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Prostate cancer (PC) is the leading cause of cancer and the second leading cause of
cancer-death among men in the Western world. About 10–20% of men with PC present
with metastatic disease at diagnosis, while 20–30% of patients diagnosed with localized
disease will eventually develop metastases. Although most respond to initial androgen-
deprivation therapy (ADT), progression to castration-resistant PC (CRPC) is universal. In
2004 the docetaxel/prednisone regimen was approved for the management of patients
with metastatic CRPC, becoming the standard first-line therapy. Recent advances have
now led to an unprecedented number of new drug approvals within the past years, provid-
ing many new treatment options for patients with metastatic CRPC. Four new drugs have
received U.S. Food and Drug Administration (FDA)-approval in 2010 and 2011: sipuleucel-
T, an immunotherapeutic agent; cabazitaxel, a novel microtubule inhibitor; abiraterone
acetate, a new androgen biosynthesis inhibitor; and denosumab, a bone-targeting agent.
The data supporting the approval of each of these agents are described in this review, as
are current approaches in the treatment of metastatic CRPC and ongoing clinical trials of
novel treatments and strategies.
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INTRODUCTION
Prostate cancer (PC) is the leading cause of cancer and the second
leading cause of cancer-death among men in the Western world
(Siegel et al., 2012). For early stage PC definitive primary treat-
ment with surgery and radiation is often curative. Unfortunately,
about 10–20% of men with PC present with metastatic disease
at diagnosis, while 20–30% of patients diagnosed with localized
disease will eventually develop metastases. Androgen-deprivation
therapy (ADT) is the mainstay of initial therapy in these patients,
and involves the use of luteinizing hormone-releasing hormone
(LHRH) drugs (agonists or antagonists; chemical castration) or
orchiectomy (surgical castration), consistently resulting in a 90–
95% reduction in circulating levels of testosterone. However,
nearly all patients will develop progressive disease, despite cas-
trate levels of androgens (testosterone level< 50 ng/mL), namely
castration-resistant prostate cancer (CRPC), after a median dura-
tion of response of 18–24 months (Hamberg et al., 2008; Sternberg,
2008). Although secondary hormonal manipulations (including
antiandrogens, and androgen-suppressing agents, such as estro-
gens and ketoconazole) can benefit a subset of men with metastatic
CRPC, this benefit is usually short-lived.
Prior to 2004, there was no treatment proven to improve
survival for men with metastatic CRPC. Mitoxantrone in com-
bination with prednisone was explicitly developed, and approved
as a palliative agent with no increase in overall survival (OS;
Tannock et al., 1996; Kantoff et al., 1999). In 2004, the doc-
etaxel/prednisone regimen was approved for the management of
patients with metastatic CRPC. This approval was based on two
landmark phase III trials (TAX 327 and SWOG 9916), which
demonstrated a survival benefit of approximately 2 months for
docetaxel in combination with either prednisone or estramus-
tine (Petrylak et al., 2004; Tannock et al., 2004). In the TAX 327
trial, patients with metastatic CRPC were randomized to receive
two different schedules of docetaxel (weekly or every 3 weeks)
plus prednisone, or mitoxantrone with prednisone. A significant
survival benefit favoring docetaxel every 3 weeks compared to
mitoxantrone [hazard ratio (HR) for death, 0.76, 95% CI, 0.62–
0.94; p= 0.009] was observed, together with an improved quality
of life, lower levels of cancer-induced bone pain, decreased serum
levels of PSA and superior response rates (Tannock et al., 2004).
In 2008, an updated survival analysis of this study showed that
the significant survival benefit with docetaxel every 3 weeks com-
pared with mitoxantrone persisted even with extended follow-up,
with a median OS of 19.2 and 16.3 months (p= 0.004), respec-
tively (Berthold et al., 2008). In the SWOG 9916 phase III trial
docetaxel in combination with estramustine was compared with
mitoxantrone in combination with prednisone, with a survival
advantage in the group treated with docetaxel (17.5 vs. 15.6
months; HR for death, 0.80; 95% CI, 0.67–0.97; p= 0.02; Petrylak
et al., 2004).
While the absolute gain in median survival of docetaxel-based
chemotherapy was statistically and clinically significant, improv-
ing its efficacy and prolonging the relatively short duration of
its benefit have continued to be matter of studies. Moreover,
until 2010, there were no treatment options conferring a survival
benefit for patients with docetaxel-refractory CRPC, although
mitoxantrone was often employed in this setting for its pallia-
tive effects on bone pain. Within the past year, several agents with
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different mechanisms of action have demonstrated efficacy, and
in 2012 therapeutic options for patients with metastatic CRPC
include four new agents approved by the U.S. Food and Drug
Administration (FDA) in 2010 and 2011. These new agents are
an immunotherapeutic product (sipuleucel-T), for the treatment
of asymptomatic or minimally symptomatic metastatic CRPC
patients; a novel taxane, cabazitaxel, which showed a survival
advantage over mitoxantrone in docetaxel-pretreated patients;
an androgen synthesis inhibitor, abiraterone acetate, which was
also reported to improve survival when evaluated against placebo
in docetaxel-pretreated patients; and a bone-targeting agent
(denosumab; Table 1).
IMMUNE-BASED THERAPY
Several approaches that attempt to treat PC by activating an
immune response against malignant cells, while overcoming
tumor-induced tolerance and avoiding autoimmune reactions
have been undertaken. Indeed, the slow-growing nature of the
disease may allow a stimulated immune system the necessary time
to generate an antitumor response and to overcome immuno-
suppressive factors. Several tissue-specific proteins, recently iden-
tified by both proteomic and microarray studies, may serve as
tumor antigens, such as PSA and prostate acid phosphatase (PAP).
Preclinical data have demonstrated the feasibility of eliciting an
antitumor immune response against PC, especially when active
immunotherapy is combined with immune checkpoint block-
ade, androgen ablation, or radiotherapy (Coffey and Isaacs, 1981;
Rhodes et al., 2002; Wang et al., 2005; Drake et al., 2006; Taylor
et al., 2006; Arlen et al., 2009; Di Lorenzo et al., 2010; Drake, 2010;
Gulley and Drake, 2011).
There are currently multiple immunological strategies in clin-
ical development for PC. Those that have generated the most
interest in recent years include the sipuleucel-T (Provenge®)
autologous PAP-loaded dendritic cell product, the GVAX allo-
geneic recombinant whole cell platform, the Prostvac-VF poxviral
vector vaccine, a PAP-encoding DNA vaccine, and approaches
that inhibit the immune checkpoints CTLA-4 (cytotoxic T-
lymphocyte-associated antigen-4; Arlen et al., 2009; Di Lorenzo
et al., 2010; Drake, 2010; Gulley and Drake, 2011).
ANTIGEN-PRESENTING CELL VACCINES
The FDA approved sipuleucel-T (APC8015, Provenge®; Dendreon
Corporation, Seattle, WA, USA) on April 29, 2010 to treat asymp-
tomatic or minimally symptomatic metastatic CRPC. Shortly
afterward, sipuleucel-T was added to the compendium of can-
cer treatments published by the National Comprehensive Cancer
Network (NCCN) as a “category 1” (highest recommendation)
treatment for CRPC.
Sipuleucel-T is a first-in-class active cellular immunother-
apy product that is manufactured by collecting peripheral blood
mononuclear cells by leukopheresis. The cells are then exposed,
for 36–44 h, to a recombinant fusion protein (PA2024) consisting
of granulocyte macrophage colony-stimulating factor (GM-CSF),
which is an established immune response-enhancing agent, and
PAP, which is expressed by cancerous and non-cancerous prostatic
cells. Activated dendritic cells, expressing PA2024 as antigens on
their cell surface, are infused back into the patient and are then
capable of sensitizing naïve T-cells to develop reactivity toward
PA2024, specifically the PAP peptide portion. The final product
also contains a variable number of T-cells, B-cells, natural killer
cells, as well as other cells. The entire process (including leuka-
pheresis and in vitro stimulation) is repeated three times, once
every 2 weeks (Higano et al., 2010).
Two randomized, placebo-controlled, phase III trials, with time
to progression (TTP) as the primary end point, were initially car-
ried out (D9901 and D9902A; Small et al., 2006). Neither of the
studies meet the primary end point although median OS was
improved by 4 months over placebo in the first study (25.9 vs.
21.4 months, p= 0.01). A post hoc pooled analysis of these two
trials in a total of 225 asymptomatic metastatic CRPC patients,
of which 147 randomized to sipuleucel-T and 78 to placebo,
confirmed the survival advantage with a 33% reduction in the
risk of death compared to placebo (HR 1.50; 95% CI, 1.10–
2.05; p= 0.011; Higano et al., 2009). Nevertheless, because OS
was not the primary endpoint in either trial, the FDA recom-
mended further data in support of the efficacy claim. A larger,
double blind, placebo-controlled, multicenter phase III study, the
IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treat-
ment) was subsequently conducted in 512 patients with asymp-
tomatic or minimally symptomatic metastatic CRPC with OS
as the primary endpoint (Kantoff et al., 2010a). Patients were
randomly assigned in a 2:1 ratio to either the treatment (341
patients) or the placebo arm (171 patients). In the final analy-
sis, sipuleucel-T arm demonstrated a 22.5% reduction in the risk
of death (HR 0.775; 95% CI, 0.61–0.98; p= 0.03) compared to the
placebo arm, together with a 4.1 months improvement in median
survival (25.8 vs. 21.7 months). Furthermore, the sipuleucel-T
group showed a 3-year survival of 32.1% compared to 23.0% in
the placebo group, indicating that a small proportion of patients
significantly benefit from treatment. Interestingly, neither PSA
response rate, nor objective radiological responses were observed.
Results from immunologic testing confirmed the drug activity on
Table 1 | New therapies in CRPC.
Trial Agent Control arm CRPC population Benefit
TAX327 (Tannock et al., 2004;
Berthold et al., 2008)
Docetaxel Mitoxantrone+prednisone Chemo-naïve Survival benefit (19.2 vs. 16.3)
IMPACT (Kantoff et al., 2010a) Sipuleucel-T Placebo Chemo-naïve (>80%) Survival benefit (25.8 vs. 21.7)
TROPIC (de Bono et al., 2010) Cabazitaxel Mitoxantrone+prednisone Docetaxel-refractory Survival benefit (15.1 vs. 12.7)
COU-AA-301 (de Bono et al., 2011) Abiraterone Placebo+prednisone Docetaxel-refractory Survival benefit (14.8 vs. 10.9)
ALSYMPCA (Parker et al., 2012b) Radium-223 Placebo Docetaxel-refractory Survival benefit (14.9 vs. 11.3)
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a biological level, with a higher titer of antibodies against PA2024
in patients receiving sipuleucel-T and who had a prolonged sur-
vival (p< 0.001). In these studies the most common adverse events
were chills, fatigue, fever, dyspnea, back pain, nausea, joint ache,
headache, local-injection reaction, most of which were mild and
transient, occurring within 1 day of infusion and resolving within
24–48 h. The most serious adverse events reported were acute infu-
sion reactions, and cerebrovascular events, the latter occurring
at a very low rate, and without statistically significant difference
between arms.
The enigmatic advantage in OS, despite the unmeet tradi-
tional end-points such as progression-free survival (PFS) or
PSA response, is an uncommon finding. The most plausible
explanation is the inadequacy of our current clinical metrics
of progression. Immune responses to vaccines require time to
develop (minimum 12 weeks), which can translate into an even
longer period to demonstrate a benefit, and the lack of dif-
ferences in progression could result from delayed antitumor
responses occurring after PSA or radiologic progression (Wol-
chok et al., 2009). It is understandable that in clinical practice,
ignoring a continually raising PSA and added risk of progres-
sion while waiting for an immune response, will have obvi-
ous ethical implications. That is why for patients with tumor-
related symptoms who need rapid tumor shrinkage to provide
palliation, or patients with rapidly progressive disease, upfront
chemotherapy should be preferred. Despite FDA approval, many
questions still remain as to how sipuleucel-T should be used.
After treatment with sipuleucel-T, many patients presumably will
move onto other treatment, many of which involving the use of
immunosuppressive steroids, but the appropriate timing for this
is unclear.
At present, there are a number of clinical trials underway
involving sipuleucel-T. In the neoadjuvant setting, currently ongo-
ing but not recruiting, the NeoACT (NEOadjuvant Active Cel-
lular ImmunoTherapy) phase II trial will assess the immune
response within prostate tissue following neoadjuvant treatment
with sipuleucel-T in patients scheduled for radical prostatectomy.
Furthermore, following radical prostatectomy subjects will be ran-
domized to receive either a booster of sipuleucel-T or no further
treatment.
VIRAL VECTOR VACCINES
Viruses are a convenient vehicle for vaccine delivery, due to
large genomes that allow for insertion of multiple genes for
tumor-associated antigens (TTAs), co-stimulatory molecules, and
cytokines; the ability to cause an inflammatory response at the
injection site with migration of APCs to the site, or to directly
infect the APCs allowing for better antigen processing; and most
of all are relatively easy and inexpensive to produce as compared
with immunotherapy products based on autologous antigen-
presenting cells. Vaccine therapies are generally well tolerated,
with the most common adverse effects being infusion reactions or
reversible flu-like symptoms within the first few days after treat-
ment. Yet, host-induced antibodies can neutralize the vector and
limit its efficacy with repeated use. Recently, a prime-boost strat-
egy has been developed, whereby replication-competent vaccinia
virus primes the immune system, and then a replication-defective
avipox virus, such as fowlpox, which is not associated with
significant neutralizing antibodies, boosts it (Acres and Bonnefoy,
2008; Amato et al., 2008; Dreicer et al., 2009; Liu, 2010).
PROSTVAC®-VF (BN ImmunoTherapeutics, Inc., Mountain
View, CA, USA) is a pox viral vaccine consisting of fowlpox and
vaccinia vectors engineered to express the human PSA gene, and a
triad of co-stimulatory molecules, known as TRICOMTM (inter-
cellular adhesion molecule-1 or ICAM-1, T-lymphocyte activa-
tion antigen CD80 or B7.1, and lymphocyte function-associated
antigen 3 or LFA-3). In a randomized, double blind, placebo-
controlled phase II trial of PROSTVAC-VF (one priming dose,
then 6 boosts over 24 weeks) in metastatic, chemotherapy-naïve,
CRPC no significant difference in PFS, primary endpoint, was
observed. However, a striking 8.5 months survival advantage was
seen in the treatment arm 3 years post-study as compared to the
control arm (25.1 vs. 16.6 months, HR 0.56; 95% CI 0.37–0.85;
p= 0.0061; Kantoff et al., 2010b). Mirroring early finding with
sipuleucel-T, there was no difference in the serum PSA responses,
or the PSA antibody titers between treatment groups, despite PSA
being the targeted tumor antigen, with no evidence of specific anti
tumor effects. The Eastern Cooperative Oncology Group recently
activated a phase II randomized study (ECOG 1809) of docetaxel
with or without PROSTVAC-VF as first-line therapy for men with
metastatic CRPC. This study will address relevant sequencing
questions and may determine whether chemotherapy is additive
to immunotherapy.
IMMUNOSTIMULATORY AGENTS
A spontaneous antitumor immune response can be induced by
a non-specific stimulation. Ipilimumab is a human monoclonal
antibody that binds to cytotoxic T-lymphocyte antigen-4 (CTLA-
4), a negative regulator of T-cell-mediated antitumor immune
responses, already approved for treating chemotherapy-refractory
metastatic melanoma patients (Hodi et al., 2010). Anti-CTLA-
4 monoclonal antibodies binding to CTLA-4 on T-cell prolongs
T-cell activation, restores T-cell proliferation, and thus amplifies
T-cell-mediated immunity, which enhances the patient’s capacity
to mount an antitumor immune response. In metastatic CRPC
patients, phase I data showed some evidence of clinical responses,
both as single agent as well as in combination with radiation
therapy (Beer et al., 2008). In a phase I dose-escalating study ipil-
imumab in combination with GM-CSF showed PSA as well as
radiological responses. A correlation between higher ipilimumab
doses and effectiveness was also shown by an increased number
of circulating activated CD8+ cells detected by flow-cytometry
(Fong et al., 2009). Two phase III trials are currently recruiting
patients: one comparing ipilimumab vs. placebo following a low-
dose of radiation to a bone lesion, in order to release tumor anti-
gens from dying tumor cells, in metastatic docetaxel-pretreated
CRPC patients (NCT00861614), and the other comparing the effi-
cacy of ipilimumab vs. placebo in asymptomatic or minimally
symptomatic patients with metastatic chemotherapy-naïve CRPC
(NCT01057810).
CYTOTOXIC CHEMOTHERAPY
In 2004, docetaxel with prednisone was approved for the
use in CRCP patients on the basis of a 2.5 months survival
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advantage over mitoxantrone and prednisone (Petrylak et al.,
2004; Tannock et al., 2004). In addition docetaxel improved
global and pain-based quality of life measures when compared
with mitoxantrone. Until recently, there were no chemothera-
peutic options approved for the treatment of CRPC after pro-
gression on docetaxel. Today a new agent has received FDA
approval, and new chemotherapies are in advanced clinical
development.
CABAZITAXEL
Cabazitaxel (Jevtana®, Sanofi-Aventis, U.S.; Bridgewater, NJ, USA)
is a novel semi-synthetic taxane, and as such stabilizes micro-
tubules thereby inhibiting their disassembly and inducing cell
cycle arrest. In contrast to other taxanes has a low affinity
for the adenosine triphosphate-dependent drug efflux pump P-
glycoprotein 1, which can be responsible for docetaxel resistance.
In 2010, a phase III trial, the TROPIC trial, randomized 755
patients with metastatic CRPC, after docetaxel failure, between
cabazitaxel plus prednisone and mitoxantrone plus prednisone
(de Bono et al., 2010). A 2.4-months survival advantage was
reported in the cabazitaxel arm (15.1 vs. 12.7 months), corre-
sponding to a 30% reduction in the risk of death (HR: 0.70;
95% CI, 0.59–0.83; p< 0.0001). Secondary end-points such as
PFS (2.8 vs. 1.4 months; p= 0.0002), response rate (14.4 vs.
4.4%; p= 0.0005), and median TTP by tumor assessment (8.8
vs. 5.4 months; p< 0.0001) also favored cabazitaxel. Comparing
the adverse event profile of these agents, the most frequent tox-
icity in the cabazitaxel group was neutropenia of grade 3 or
higher (82 vs. 58%). The incidence of febrile neutropenia was
also higher with cabazitaxel (8 vs. 1%), as was diarrhea (6 vs.
<1%). Treatment-related deaths, primarily for infectious com-
plications and renal failure, were more frequent with cabazitaxel.
The FDA approved cabazitaxel in combination with prednisone in
June 2010. Special attention should be given to prevent febrile neu-
tropenia and infections with primary prophylactic use of G-CSF
in high-risk patients. It is currently ongoing a phase III ran-
domized trial (FIRSTANA) in chemo-naïve patients with CRPC,
which compared two different doses of cabazitaxel, plus pred-
nisone vs. docetaxel plus prednisone. Primary objective is OS
(NCT01308567).
HORMONAL THERAPY
Androgens are the primary regulators of PC cell growth and
proliferation, and indeed ADT nearly always leads to a PSA
response. However, despite the initial response to first-line hor-
monal therapy, the median duration of response is 18–24 months,
and the development of CRPC is inevitable (Hamberg et al.,
2008; Sternberg, 2008). It is well known that CRPC involves
in most cases the reactivation of the androgen receptor (AR)
in the absence of gonadal testosterone. Continued AR activa-
tion occurs likely from one or more of several mechanisms
including: amplification or overexpression of the AR gene, muta-
tions of the AR gene, changes in the levels of AR cofac-
tors, increased expression of enzymes involved in androgen
synthesis, ligand-independent activation of AR, and enhanced
intracellular conversion of adrenal androgens to testosterone and
dihydrotestosterone (Dayyani et al., 2011). Clinical PC progression
reflects a gradual shift from endocrine sources of androgens (espe-
cially from the testes and adrenal glands) to paracrine, autocrine,
and intracrine sources within the tumor microenvironment (Stan-
brough et al., 2006; Mizokami et al., 2009). Hence, CRPC tumors
are not uniformly hormone-refractory and may remain sensi-
tive to therapy directed against the AR axis. Indeed several new
classes of AR-targeting agents are now in clinical development,
including CYP17 inhibitors that suppress the steroidogenesis,
such as abiraterone acetate, and potent AR antagonists, such as
MDV3100.
ABIRATERONE
Abiraterone acetate (Zytiga®, Janssen-Cilag International NV)
is an orally administered inhibitor of 17 α-hydroxylase and
C17,20-lyase referred to as the CYP17 complex, a member of the
cytochrome P450 family. CYP17 is a microsomal enzyme and cat-
alyzes 2 reactions, the 17 α-hydroxylation of pregnenolone and
progesterone to 17αOH-pregnenolone and 17αOH-progesterone,
respectively, and the subsequent C17,20-lyase reaction to form
the corresponding 17-keto androgens, namely dehydroepiandros-
terone and androstenedione, which are precursors of all other
androgens, including testosterone. Inhibition of the CYP17 com-
plex leads to accumulation of upstream mineral corticoids and
reduction of downstream steroids including testosterone and
estradiol. In fact, abiraterone side effects are dependant on min-
eralocorticoid excess, and include hypokalemia, hypertension,
peripheral edema, and headaches (Reid et al., 2008). These adverse
events are in most cases controlled by administration of corti-
costeroids or aldosterone antagonist. Abiraterone treatment has
been shown to suppress testosterone levels, with reduction in PSA
level, regression of radiological lesions, and improvement in symp-
toms in phase I and II studies conducted in docetaxel-naïve and
docetaxel-pretreated patients (Attard et al., 2008, 2009a; Danila
et al., 2010; Reid et al., 2010; Ryan et al., 2010). These results
led to two randomized placebo-controlled phase III trials testing
the efficacy of abiraterone in improving survival in patients with
metastatic CRPC. A randomized, double blind, placebo-controlled
trial (COU-AA-301) compared abiraterone plus prednisone with
placebo plus prednisone in 1,195 docetaxel-pretreated patients
with CRCP (de Bono et al., 2011). Based on a 4 months improve-
ment in OS found at the interim analysis (14.8 vs. 10.9 months;
HR 0.65; 95% CI 0.54–0.77; p< 0.0001), as well as significant
improvements in PFS (5.6 vs. 3.6 months; p< 0.001) and over-
all response rate (38 vs. 10%; p< 0.001), abiraterone was FDA
approved in April 2011 for metastatic CRPC patients that previ-
ously received docetaxel-based chemotherapy. A second phase III
trial (COU-AA-302) comparing abiraterone plus prednisone vs.
placebo plus prednisone in patients with metastatic CRPC who
are chemotherapy-naïve has recently completed accrual. Primary
end-points of the study are OS and PFS (NCT00887198). The final
results are due for reporting in the next months.
MDV3100
MDV3100 is a potent novel small AR antagonist that blocks testos-
terone binding to AR, and prevents the nuclear translocation
and DNA binding of the ligand-AR complex. Unlike bicalu-
tamide, MDV3100 does not possess agonist activity when AR
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is overexpressed (Attard et al., 2009b; Tran et al., 2009). In a
phase I/II study of 140 patients to determine the maximum tol-
erated dose, safety, pharmacokinetics, and antitumor activity of
MDV3100, an antitumor effect was seen in both chemotherapy-
naïve and docetaxel-pretreated patients (Scher et al., 2010). Fifty-
six percent of patients had 50% or greater PSA decline, 22%
of the patients with measurable disease had a partial response,
and 56% of the patients with bone disease had a stable dis-
ease; the median TTP for all patients was of 47 weeks. Based on
these encouraging results, a phase III trial (AFFIRM) was con-
ducted to compare MDV3100 vs. placebo in metastatic CRPC
patients who had previously received docetaxel-based chemother-
apy. Results are pending (NCT00974311). A second phase III
trial (PREVAIL) evaluating the impact of MDV3100 vs. placebo
in chemotherapy-naïve patients with metastatic CRCP, with
OS and PFS as co-primary end-points, is currently recruiting
(NCT01212991).
BONE-TARGETING AGENTS
Patients with CRPC have an increased risk of skeletal-related
events (SREs), including fracture, progressive bone pain, spinal
cord compression, due to reduced bone mineral density from cas-
tration, frequent glucocorticoid use, other than disease process.
More than 80–90% of patients with metastatic CRPC will develop
bone metastases, resulting in substantial morbidity and a sig-
nificant detrimental effect on quality of life. In a double blind,
phase III trial in men with metastatic CRPC the intravenous bis-
phosphonate zoledronic acid (4 mg intravenously every 3 weeks)
showed a significant reduction in the rate of SREs as compared
to placebo (44.2 vs. 33.2%; p= 0.021), with a delay in the time
to a first SRE (Saad et al., 2002). Patients who were treated
with zoledronic acid also had significantly decreased in urinary
markers of bone resorption. An analysis of the long-term effi-
cacy of zoledronic acid in 122 patients from the original study
confirmed a significant trend in improved outcomes, with an
ongoing risk of experiencing a SRE reduced by 36% (Saad et al.,
2004).
Denosumab (XGEVA®, Amgen, Thousand Oaks, CA, USA), is
a fully human monoclonal antibody against receptor activator of
nuclear factor-kappa B (RANK) ligand, a key protein secreted by
stromal cells and osteoblast in response to growth factors released
by tumor cells, which promotes osteoclast activation by binding
the RANK-receptor on their surface. The ligand-receptor inter-
action causes the activation of survival and proliferation path-
ways in osteoclasts that trigger bone resorption (Li et al., 2000;
Mundy et al., 2001). Denosumab (60 mg) was first evaluated in a
double blind phase III trial of ADT-related bone loss compared
with placebo administered every 6 months (Smith et al., 2009).
After 2 years, the lumbar spine bone mineral density increased
by 5.6% in the denosumab arm, whereas it decreases by 1.0% in
the placebo arm (p< 0.001), with similar increases in the bone
mineral density of the total hip, femoral hip, and distal third of
the radius. These improvements led to a significant decreased
3 year incidence of new vertebral fractures among patients in
the denosumab arm (p= 0.006). In a second trial denosumab
(120 mg subcutaneously every 4 weeks) was compared with zole-
dronic acid (4 mg endovenously every 4 weeks), in 1,904 men with
bone metastases from CRPC (Fizazi et al., 2011). In this study,
denosumab significantly delayed the time to first on-study SRE
(HR 0.82; 95% CI, 0.71–0.95; p= 0.008), with a median time
of first on-study SRE of 20.7 months compared to 17.1 months
in patients receiving zoledronic acid, a difference of 3.6 months,
and an overall risk reduction of 18%. Overall survival (HR 1.03;
95% CI, 0.91–1.17; p= 0.65) and time to cancer progression
(HR 1.06; 95% CI, 0.95–1.18; p= 0.30) were similar between
the two treatment arms. Adverse event rates were similar, with
primarily fevers, constipation, and joint pain; rates of hypocal-
cemia were higher in the denosumab arm (13 vs 6%; p< 0.0001),
with osteonecrosis of the jaw being more frequent in the exper-
imental arm (p= 0.09). The FDA approved in November 2010
denosumab for the prevention of SREs in men with metastatic
CRPC and bone metastases. Phase III studies evaluating the abil-
ity of these agents to delay the development of bone metastases
are ongoing.
Alpharadin (radium-223 chloride) is a first-in-class, highly tar-
geted α-emitting radiopharmaceutical under clinical evaluation
for CRPC patients with bone metastases. By carrying micro-
scopic amounts of radium-223, which acts as a calcium mimic,
alpharadin delivers high energy, short range irradiation that
induces double-stranded DNA breaks with lower penetration
to surrounding tissues, compared with the β-emitting radio-
pharmaceuticals samarium-153 and strontium-89. In the phase
III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer)
alpharadin has shown both delayed time to first SRE and an
unprecedented OS benefit (Parker et al., 2012a; Sartor et al., 2012).
The ALSYMPCA study was stopped early after a pre-planned
efficacy interim analysis, on the basis of achieving a statistically
significant improvement in OS (median OS 14.0 vs. 11.2 months,
HR= 0.699; p= 0.0022). Updated data showed that alpharadin
improved OS by 44% (HR= 0.695; p= 0.00007), resulting in
FIGURE 1 |The current treatment paradigm of CRPC.
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a 30.5% reduction in the risk of death compared to placebo
(Parker et al., 2012b). The median OS benefit with alpharadin
was 3.6 months in this updated analysis (14.9 months in patients
given alpharadin vs. 11.3 months with placebo). Alpharadin has
been granted Fast Track designation by the FDA.
CONCLUSIONS
The availability of multiple new treatments in patients with
metastatic CRPC is the current challenge for the clinicians, now
facing the choice of the right treatment at the right time (Figure 1).
In our view, sipuleucel-T would be the most appropriate treatment
for naïve patients with asymptomatic to minimally symptomatic
bone- or lymph node-metastatic CRPC, which do not require
immediate treatment with chemotherapy. Indeed, symptomatic
patients would be probably better served with chemotherapy
as sipuleucel-T administration leads to almost no response, as
well as TTP is not affected. It can be anticipated that lack of
availability, complexity of administration, approval of the center
by the manufacturer, and cost issues will probably limit clin-
ical utilization of sipuleucel-T in the near future. In patients
with symptomatic disease or visceral metastases, or in those
who have a rapidly progressive disease, chemotherapy should
be administered, and docetaxel with prednisone is the preferred
first choice. In docetaxel-pretreated patients, phase III trials sup-
port the use of cabazitaxel or abiraterone, preferred in frail men,
each given with prednisone. Docetaxel retreatment may also be
appropriate, especially in patients with a good initial response
to docetaxel and subsequent discontinuation for reasons other
than disease progression. In addition to the above approaches,
the use of bone health-promoting agents such as denosumab or
zoledronate should be strongly considered for men with bone
metastatic disease to prevent pathological fractures, spinal cord
compression or the need for radiation or surgery for skeletal
complications.
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